US · MDGL
Madrigal Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- West Conshohocken, PA 19428
- Website
- madrigalpharma.com
Price · as of 2025-12-31
$513.72
Market cap 9.81B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $252.27 | -50.89% |
| Intrinsic Value(DCF) | $583,183.26 | +113,421.62% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $156.80 | $62.72 | $35.91 | $0.00 | $1,354.89 |
| 2012 | $343.00 | $137.20 | |||
| 2013 | $179.55 | ||||
| 2014 | $81.20 | ||||
| 2015 | $8.75 | ||||
| 2016 | $15.73 | ||||
| 2017 | $138.75 | ||||
| 2018 | $125.57 | ||||
| 2019 | $85.86 | ||||
| 2020 | $117.84 | ||||
| 2021 | $95.58 | ||||
| 2022 | $241.64 | ||||
| 2023 | $255.32 | ||||
| 2024 | $331.41 | $8.95 | $0.00 | ||
| 2025 | $435.62 | $252.27 | $7.79 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Madrigal Pharmaceuticals, Inc.'s (MDGL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $252.27
- Current price
- $513.72
- AI upside
- -50.89%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$583,183.26
+113,421.62% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MDGL | Madrigal Pharmaceuticals,… | $513.72 | 9.81B | -51% | +113,422% | — | — | -33.90 | 16.22 | 10.20 | -34.57 | — | 16.42 | 94.14% | -31.31% | -30.08% | -42.49% | 761.60% | -25.05% | 0.59 | -13.45 | 4.01 | 3.60 | -0.59 | -4132.00% | 43205.00% | -5842.00% | -1.94% | -0.61 | 482.24% | 0.00% | 0.00% | 0.00% | -30.47 | -48.12 | 9.54 | 7.47 |
| ABVX | Abivax S.A. | $121.28 | 7.95B | -67% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | — | 27.39 | 100.00% | -1602.89% | -1633.08% | -148.98% | 2618.19% | -66.22% | 2.40 | -41.33 | 1.84 | 1.72 | 0.27 | -1837.00% | 13354.00% | 5429.00% | -36.31% | -1.66 | 2341.68% | 0.00% | 0.00% | 0.00% | -2.19 | -2.45 | 35.14 | -3.71 |
| BAX | Baxter International Inc. | $20.37 | 10.48B | +17% | -61% | — | — | -10.55 | 1.65 | 0.90 | 23.68 | -27.93 | -3.19 | 30.05% | -2.74% | -8.51% | -14.62% | -1.88% | -4.18% | 1.63 | -1.06 | 2.31 | 1.31 | 10.49 | 3780.00% | 572.00% | -4222.00% | 3.20% | 0.28 | 1.97% | 3.45% | -36.40% | 39.56% | -58.89 | 56.15 | 1.61 | 2.13 |
| BMRN | BioMarin Pharmaceutical I… | $61.73 | 11.86B | +37% | -52% | -36% | -40% | 32.84 | 1.88 | 3.56 | 18.32 | — | 2.02 | 77.13% | 16.56% | 10.83% | 5.94% | 7.50% | 4.79% | 0.10 | 48.95 | 5.21 | 3.25 | -1.25 | -1855.00% | 1287.00% | 5249.00% | 6.33% | 1.09 | 14.09% | 0.00% | 0.00% | 3.68% | 19.67 | 14.48 | 3.26 | 5.75 |
| CAI | Caris Life Sciences, Inc. | $20.14 | 5.68B | +132% | +659% | — | — | -507.35 | 59.84 | 42.54 | 2965.27 | — | 61.91 | 66.40% | 5.56% | -66.25% | 7.09% | -3.82% | -9.27% | 0.00 | 0.79 | 7.85 | 7.17 | -70.09 | -2963.00% | 9697.00% | -12637.00% | 0.19% | 0.65 | -5.66% | 0.00% | 0.00% | 3.35% | 748.01 | 504.44 | 41.56 | 36.41 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | -56% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MRNA | Moderna, Inc. | $53.57 | 20.93B | -39% | -52% | — | +298% | -7.28 | 2.38 | 10.57 | -6.53 | — | 2.38 | 55.35% | -158.13% | -145.16% | -28.87% | -65.47% | -21.31% | 0.22 | — | 3.29 | 3.01 | 0.27 | -2168.00% | -3923.00% | -4908.00% | -10.05% | -0.94 | -43.98% | 0.00% | 0.00% | 0.00% | -5.42 | -8.07 | 8.58 | 3.94 |
| RNA | Avidity Biosciences, Inc. | $14.75 | 2.28B | +47% | -35% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| RYTM | Rhythm Pharmaceuticals, I… | $92.73 | 6.19B | -37% | +215% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
| TECH | Bio-Techne Corporation | $59.00 | 9.23B | -19% | -63% | -94% | -90% | 116.45 | 4.45 | 7.01 | 40.71 | — | 14.94 | 64.80% | 8.38% | 6.02% | 3.68% | 3.36% | 2.79% | 0.23 | 12.02 | 3.46 | 2.10 | 1.30 | -5619.00% | 523.00% | 866.00% | 3.00% | 1.64 | 11.31% | 0.59% | 68.70% | 3.82% | 86.35 | 34.42 | 7.24 | 9.42 |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
- CEO
- William J. Sibold
- Employees
- 528
- Beta
- -1.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($583,183.26 ÷ $513.72) − 1 = +113,421.62% (DCF, example).